3933.HK Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 апр. 2024 @ 11:08):

The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products...

Stats
Объем за сегодня	2.85M
Средний объем	4.02M
Рыночная капитализация	16.77B
EPS	HKD0 ( 2024-03-26 )
Last Dividend	HKD0.131 ( 2023-09-14 )
Next Dividend	HKD0 ( N/A )
P/E	5.63
ATR14	HKD0.00700 (0.08%)

Объем Корреляция

Длинно: 0.04 (neutral)

Кратко: -0.25 (neutral)

Signal:(42.349) Neutral

United Laboratories Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

United Laboratories Корреляция - Валюта/Сырье

-0.36
( neutral )

-0.17
( neutral )

0.00
( neutral )

-0.18
( neutral )

0.29
( neutral )

United Laboratories Финансовые показатели

Annual	2023
Выручка:	HKD13.74B
Валовая прибыль:	HKD6.33B (46.11 %)
EPS:	HKD1.490

FY	2023
Выручка:	HKD13.74B
Валовая прибыль:	HKD6.33B (46.11 %)
EPS:	HKD1.490

FY	2022
Выручка:	HKD11.33B
Валовая прибыль:	HKD4.97B (43.84 %)
EPS:	HKD0.870

FY	2021
Выручка:	HKD9.70B
Валовая прибыль:	HKD4.21B (43.40 %)
EPS:	HKD0.560

Financial Reports:

No articles found.

United Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.0801 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.196 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

United Laboratories Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.42 - Stable (11.58%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.156	2008-05-26
Last Dividend	HKD0.131	2023-09-14
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	15	--
Total Paid Out	HKD1.398	--
Avg. Dividend % Per Year	0.00%	--
Score	2.65	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.42
Div. Directional Score	7.66	--

Next Divdend (Est)
(2024-11-19)

HKD0.150 Estimate 2.95 %

Dividend Stability

0.24 Very Poor

Dividend Score

2.65

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2362.HK	No Dividend Player	2023-06-01	Annually	0.00%
1349.HK	Ex Dividend Junior	2023-06-05	Annually	0.00%
0393.HK	Ex Dividend Knight	2023-09-14	Semi-Annually	0.00%
6677.HK	Ex Dividend Junior	2023-06-01	Annually	0.00%
1899.HK	Ex Dividend Junior	2023-06-13	Annually	0.00%
0927.HK	Ex Dividend Knight	2023-08-29	Semi-Annually	0.00%
0057.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
2883.HK	Ex Dividend Knight	2023-06-07	Annually	0.00%
1480.HK	Ex Dividend Knight	2023-06-08	Sporadic	0.00%
0551.HK	Ex Dividend Junior	2023-09-12	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.197	1.500	6.07	9.10	[0 - 0.5]
returnOnAssetsTTM	0.129	1.200	5.72	6.86	[0 - 0.3]
returnOnEquityTTM	0.223	1.500	8.64	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.08	0.800	4.60	3.68	[1 - 3]
quickRatioTTM	1.528	0.800	5.72	4.57	[0.8 - 2.5]
cashRatioTTM	0.643	1.500	7.54	10.00	[0.2 - 2]
debtRatioTTM	0.0714	-1.500	8.81	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.659	2.00	9.78	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.400	2.00	9.80	10.00	[0 - 20]
debtEquityRatioTTM	0.118	-1.500	9.53	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.461	1.000	5.65	5.65	[0.2 - 0.8]
operatingProfitMarginTTM	0.231	1.000	7.38	7.38	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.798	1.000	6.68	6.68	[0.2 - 2]
assetTurnoverTTM	0.654	0.800	8.98	7.18	[0.5 - 2]
Total Score				10.90

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	5.63	1.000	9.53	0	[1 - 100]
returnOnEquityTTM	0.223	2.50	9.12	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.400	2.00	9.87	10.00	[0 - 30]
dividendYielPercentageTTM	2.35	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.659	2.00	9.78	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0872	1.000	-0.321	0	[0.1 - 0.5]
Total Score				4.42

United Laboratories

The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.